Search

The article offers information on the revision of the McDonald Criteria for diagnosis of multiple sclerosis (MS). It states that International Panel on Diagnosis of MS reviewed the McDonald Criteria. It mentions that the panel stressed that the McDonald Criteria should only be applied to those patients who present a typical clinically isolated syndrome (CIS).

A recent investigation reported, for the first time, an association between variants in the IFIH1-GCA-KCNH7 locus and multiple sclerosis (MS). We sought to replicate this genetic association in MS with a new independent MS cohort composed of French Caucasian MS trio families. The two most significant IFIH1 single nucleotide polymorphisms, rs1990760 and rs2068330, reported as involved in MS susceptibility, were genotyped in 591 French Caucasian MS trio families, and analyzed using the transmission/disequilibrium test. No association with MS was found (rs1990760, P=0.45 and rs2068330, P=0.27). Similarly, no significant association was detected after stratification for HLA-DRB1*1501 carriers. Reasons that may explain this discrepancy between the original report and our study are discussed.European Journal of Human Genetics (2009) 17, 844–847; doi:10.1038/ejhg.2008.259; published online 21 January 2009 [ABSTRACT FROM AUTHOR]

We describe one report of a cervical dysplasia in a patient receiving natalizumab for multiple sclerosis. Other cases were identified in the WHO's global individual case safety report database, VigiBase®. These data underline the importance of monitoring HPV infection in patients with MS treated with natalizumab. [ABSTRACT FROM AUTHOR]

Abstract: We explored the parameters of central and peripheral tolerance in patients with stable relapsing–remitting multiple sclerosis, treated or not with IFN-β. TREC-positive T cells were lower in patients compared with controls, mainly in CD4+ subset, compatible with a thymus dysfunction or an expansion of peripheral lymphocytes. Compared to controls, the frequency of activated CD4+CD25+ T cells was higher in patients without modification of the CD4+CD25high T cell proportion. The IFN-β-treatment did not modify the TREC-positive cell frequency nor the naive/memory T cell subset percentage but was associated with lower blood lymphocyte count and a lower frequency of CD4+CD45RChigh subset. [Copyright &y& Elsevier]